![Shengkan Jin](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Aktive Positionen von Shengkan Jin
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Mito BioPharm LLC
![]() Mito BioPharm LLC Pharmaceuticals: MajorHealth Technology Mito BioPharm LLC is an American pharmaceutical company that focuses on developing therapies for non-alcoholic fatty liver disease (NAFLD), specifically non-alcoholic steatohepatitis (NASH) and type 2 diabetes. NAFLD is a range of conditions that start with fat accumulation in the liver and can progress to inflammation, fibrosis, cirrhosis, and even liver cancer. Mito BioPharm's drug discovery pipeline and intellectual property are aimed at addressing these conditions. | Direktor/Vorstandsmitglied | 01.01.2012 | - |
Technik-/Wissenschafts-/F&E-Leiter | 01.01.2012 | - | |
Gründer | 01.01.2012 | - |
Karriereverlauf von Shengkan Jin
Statistik
International
Vereinigte Staaten | 2 |
Operativ
Director/Board Member | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Sektoral
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Mito BioPharm LLC
![]() Mito BioPharm LLC Pharmaceuticals: MajorHealth Technology Mito BioPharm LLC is an American pharmaceutical company that focuses on developing therapies for non-alcoholic fatty liver disease (NAFLD), specifically non-alcoholic steatohepatitis (NASH) and type 2 diabetes. NAFLD is a range of conditions that start with fat accumulation in the liver and can progress to inflammation, fibrosis, cirrhosis, and even liver cancer. Mito BioPharm's drug discovery pipeline and intellectual property are aimed at addressing these conditions. | Health Technology |
- Börse
- Insiders
- Shengkan Jin
- Erfahrung